DiaPep277

DRUG5 trials

Sponsors

DeveloGen Israel, Ltd., Andromeda Biotech Ltd., Rabin Medical Center

Conditions

Diabetes, AutoimmuneType 1 DiabetesType 1 Diabetes Mellitus

Phase 2

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

TerminatedNCT00058981

DeveloGen Israel, Ltd.Diabetes, Autoimmune

Start: 2002-10-31End: 2007-05-31Target: 100Updated: 2009-03-19

Phase 3

Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

CompletedNCT00615264

Andromeda Biotech Ltd.Type 1 Diabetes

Start: 2005-09-30End: 2012-01-31Updated: 2016-06-06

Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes

CompletedNCT00644501

Andromeda Biotech Ltd.Type 1 Diabetes

Start: 2008-09-30End: 2013-06-30Updated: 2013-07-11

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

CompletedNCT01103284

Andromeda Biotech Ltd.Type 1 Diabetes Mellitus

Start: 2010-04-30End: 2014-10-31Updated: 2016-05-26

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

TerminatedNCT01460251

Rabin Medical CenterType 1 Diabetes

Start: 2012-01-31End: 2015-02-28Updated: 2015-03-19

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01